Deals
Takeda's Dissident Holders Keep Trying to Kill Shire Deal
This article is for subscribers only.
They have little chance of success, but the shareholder group trying to derail Takeda Pharmaceutical Co.’s $62 billion purchase of U.K.-listed Shire Plc is making last-minute attempts to win over investors.
The dissident holders account for only about 1 percent of Takeda’s shares outstanding, but the group is raising its profile as the Japanese drugmaker inches toward completing its largest deal ever. The group has put out invitations to shareholders for emergency meetings this week after the deal is expected to be approved by Europe on Tuesday in its final major regulatory hurdle.